LEARNING PROGRAM REGISTRATION

BACK About the Program

Join Dr. Jonathan Silverberg for an engaging accredited evening featuring international expertise and real world clinical perspectives on the management of moderate-to-severe atopic dermatitis. Interactive sessions pair self‑assessment with expert insights on AD treatments, IL‑13 pathways, and biologic differentiation, plus personalized feedback to support improved patient outcomes.

Program Learning Objectives

  • Explain the root causes of AD inflammation and how these are targeted by advanced therapies
  • Describe key findings and share clinical pearls from recent clinical trials and real-world experience to differentiate advanced therapies in moderate-to-severe AD
  • Develop strategies for timely initiation of advanced treatment for moderate-to-severe AD to optimize clinical outcomes, reduce disease burden and reduce risk of relapse
  • Evaluate and refine their approach to individualized treatment of moderate-to-severe AD through evidence-based decision-making

May 26th, 2026

Arrival
5:30 pm EDT
Presentation Start
6:00 pm EDT
Presentation End
7:00 pm EDT
Add to Calendar 05/26/2026 06:00 pm 05/26/2026 07:00 pm America/Toronto Cross-Border Perspectives in Atopic Dermatitis

Thank you for your interest in the presentation of the program titled Cross-Border Perspectives in Atopic Dermatitis.

SPEAKER: Jonathan Silverberg, MD, PhD, MPH, FAAD
MODERATOR: Maxwell Sauder, MD, FRCPC

You can join the event either in person or virtually.

IN-PERSON ATTENDANCE:
Sheraton Gateway Hotel, Terminal 3 Toronto Amf, Toronto, ON, L5P 1C4

CONNECTION INSTRUCTIONS:
Click here to join the meeting on Zoom: https://us02web.zoom.us/webinar/register/WN_2jdA3A4RQPCNKFf5NaE_mg
Meeting ID: 851 2237 9294
Password: 442432

*Detailed connection instructions are provided further below.

Learning Objectives:
Upon completion of this program, participants will be better able to:
  • Explain the root causes of AD inflammation and how these are targeted by advanced therapies
  • Describe key findings and share clinical pearls from recent clinical trials and real-world experience to differentiate advanced therapies in moderate-to-severe AD
  • Develop strategies for timely initiation of advanced treatment for moderate-to-severe AD to optimize clinical outcomes, reduce disease burden and reduce risk of relapse
  • Evaluate and refine their approach to individualized treatment of moderate-to-severe AD through evidence-based decision-making
This program is brought to you by The CPD Network, a non-profit organization. It has received an educational grant and in-kind support from Eli Lilly Canada Inc.

You will receive a reminder by email in the days prior to the event.

For any questions related to this hybrid, please contact implementation@livagency.ca.

 Sheraton Gateway Hotel Terminal 3 Toronto Amf Toronto, ON L5P 1C4 Virtual: https://us02web.zoom.us/webinar/register/WN_2jdA3A4RQPCNKFf5NaE_mg

Sheraton Gateway Hotel
Terminal 3 Toronto Amf
Toronto, ON L5P 1C4

Speaker(s) Jonathan Silverberg, MD, PhD, MPH, FAAD
Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Moderator(s) Maxwell Sauder, MD, FRCPC
Assistant Professor in the Division of Dermatology at the University of Toronto
Onco-Dermatologist at Princess Margaret Cancer Centre, Toronto Dermatology Centre
Toronto, ON






This program is brought to you by The CPD Network, a non-profit organization. It has received an educational grant and in-kind support from Eli Lilly Canada Inc.